Immune cell therapy shows promise for aggressive blood cancer
NCT ID NCT04661020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment called CD19 CAR-T therapy for people newly diagnosed with a fast-growing type of blood cancer called high-risk large B-cell lymphoma. The therapy uses a patient's own immune cells, modified to better attack cancer cells. The main goal is to see how many patients achieve complete remission three months after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital，College of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
- New hope: drug may prevent dangerous reactions to cancer immunotherapy
- AI takes on lymphoma: personalized treatment strategy under trial
- Affordable CAR-T breakthrough: academic therapy offers new hope for blood cancer patients
- New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo
- Experimental CAR-T therapy takes on tough lymphoma